Subscribe To
ORIC / 2 Falling Knives to Catch
ORIC News
By GlobeNewsWire
October 17, 2023
ORIC Pharmaceuticals to Present Initial Phase 1b Clinical Data for ORIC 114 in EGFR/HER2 Exon 20 Mutated NSCLC at the European Society of Medical Oncology (ESMO) Congress 2023
Company to host a conference call and webcast on Saturday, October 21, 2023, at 9:00 am ET featuring Dr. Alexander Spira to discuss initial data and p more_horizontal
By Zacks Investment Research
October 16, 2023
Oric Pharmaceuticals, Inc. (ORIC) Upgraded to Buy: What Does It Mean for the Stock?
Oric Pharmaceuticals, Inc. (ORIC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This more_horizontal
By GlobeNewsWire
September 20, 2023
ORIC Pharmaceuticals to Participate in the 2023 Cantor Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept. 20, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology com more_horizontal
By GlobeNewsWire
August 30, 2023
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO and SAN DIEGO, Aug. 30, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focu more_horizontal
By The Motley Fool
June 26, 2023
Why Shares of Oric Pharmaceuticals Jumped Monday
Oric Pharmaceuticals specializes in oncology therapies. The company said the private placement will help it fund operations through the end of 2025. more_horizontal
By Seeking Alpha
March 15, 2023
ORIC Pharma: Small Pfizer Deal, Cash, And A Set Of Very Early Stage Assets
ORIC has a few early stage cancer targeting molecules. In December, Pfizer made a small $25mn deal with it for the lead asset. more_horizontal
By GlobeNewsWire
June 2, 2022
ORIC Pharmaceuticals to Present at the Jefferies Healthcare Conference
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June 02, 2022 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology comp more_horizontal
By The Motley Fool
March 22, 2022
Why ORIC Pharmaceuticals Stock Is Crashing Today
The company discontinued development of its lead clinical program. more_horizontal